The 4Rs of Japanâs Equity Market Resurgence
by Stephen Way, CFAÂŽ, SVP, Head of Global & Emerging Markets Equities, AGF Investments Inc. The 4Rs of…
Whatâs in Store for Central Bank Policy?
by David Stonehouse, SVP & Head of North American and Specialty Investments, AGF Investments Inc. As many as…
Could European Equities Catch Up in 2025?
by Richard McGrath, Portfolio Advisor, AGF Investments Could European Equities Catch Up in 2025? Improving fundamentals and attractive…
U.S. Equities: A Mixed Bag of Opportunity and Risk
2025 returns look positive, but may be subject to potentially significant shifts in the macro backdrop.
Will U.S. Tariffs Rain on Canadaâs Equity Parade?
by Mike Archibald, Portfolio Manager, AGF Investments Canada's Investment landscape has largely improved this past year and we…
The Return of Policy Risk
by Kevin McCreadie, MBA, CFAÂŽ, CEO and Chief Investment Officer, AGF Management Ltd. We believe 2025 will be…
Why the Trump Trade May Be More Complicated Than Some Investors Think
by Kevin McCreadie, MBA, CFAÂŽ, CEO and Chief Investment Officer, AGF Management Ltd. AGFâs CEO and Chief Investment…
Why âWho Winsâ Could Matter to Investors
by The Editor's Desk, AGF Investments This yearâs presidential race has been framed as an existential battle between…
Why Japan May Be the Next Semiconductor Powerhouse
by Grace Huang, Senior Analyst, AGF Investments Japanâs equity market has been hit hard by the recent correction…
When Bad News is Actually Bad News for Investors
by Kevin McCreadie, MBA, CFAÂŽ, CEO and Chief Investment Officer, AGF Management Ltd. Kevin McCreadie, AGFâs CEO and…
Why Global Financial Markets Are in Extreme Flux
by AGF Investments' Investment Management Team, AGF Investments Members of AGF Investmentsâ investment management team weigh in on…
Mid-Year Outlook: Seven Questions That Could Shape Markets in the Second Half of 2024
by Kevin McCreadie, John Christofilos, Bill DeRoche, Rune Sollihaug, David Stonehouse, Stephen Way, AGF Investments Members of AGF…
An Investorâs Guide to GLP-1 Drugs: Beyond Biopharma Stocks
by Ling Han, M.Sc., MBA, CFAÂŽ, Analyst, AGF Investments Inc. The market enthusiasm for glucagon-like peptide 1 (GLP-1)…
The Impact of AI on Industrials Stocks
with Lazar Naiker, Research Analyst, AGF Investments AGF Investments analyst Lazar Naiker explains the link between artificial intelligence…
Interest Rates Expectations Still in Flux, Chinaâs Equity Market Back in Play
by David Stonehouse & Regina Chi, AGF Investments A mid-week analysis of whatâs happening in global financial markets…
